p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19

American Journal of Pathology

Volumn 157, Issue 4, 2000, Pages 1393-1403

  Hartmann, Wolfgang ^a   Waha, Andreas ^a   Koch, Arend ^a   Goodyer, Cynthia G ^b   Albrecht, Steffen ^c   Von Schweinitz, Dietrich ^d   Pietsch, Torsten ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; GENE PRODUCT; MESSENGER RNA;

ALLELE; ARTICLE; CHROMOSOMAL LOCALIZATION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE LOCATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENOME IMPRINTING; HEPATOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

EID: 0033815532     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64652-4     Document Type: Article

References (63)

1. Primary hepatic tumors of childhood
2. Three non-overlapping regions of chromosome arm 11p allele loss identified in infantile tumors of adrenal and liver
3. Loss of heterozygosity on chromosome 1 in human hepatoblastoma
4. Loss of maternal alleles on chromosome arm 11p in hepatoblastoma
5. p57(KIP2), A structurally distinct member of the p21CIP1Cdk family, is a candidate tumor suppressor gene
6. Cloning of p57(KIP2), a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution
7. Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57(KIP2) requires binding to proliferating cell nuclear antigen
8. Altered cell differentiation and proliferation in mice lacking p57(KIP2) indicates a role in Beckwith-Wiedemann syndrome
9. Ablation of the CDK inhibitor p57(KIP2) results in increased apoptosis and delayed differentiation during mouse development
10. Low frequency of p57(KIP2) mutation in Beckwith-Wiedemann syndrome
11. An imprinted gene p57(KIP2) is mutated in Beckwith-Wiedemann syndrome
12. New p57(KIP2) mutations in Beckwith-Wiedemann syndrome
13. Coding mutations in p57(KIP2) are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumors
14. Genomic imprinting of human p57(KIP2) and its reduced expression in Wilms tumors
15. Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57(KIP2), on chromosome 11p15
16. Chromosome 11p15.5 regional imprinting: Comparative analysis of KIP2 and H19 in human tissues and Wilms' tumors
17. Parental genomic imprinting of the human IGF2 gene
18. Monoallelic expression of the human H19 gene
19. The product of the H19 gene may function as an RNA
20. Igf2 imprinting does not require its own DNA methylation or H19 RNA
21. Tumor suppressor activity of the H19 RNA
22. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms tumor
23. Inactivation of H19, an imprinted and putative tumor repressor gene, is a preneoplastic event during Wilms' tumorigenesis
24. Genomic imprinting in mammals
25. Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma
26. Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma
27. Variable imprinting of H19 and IGF2 in fetal cerebellum and medulloblastoma
28. Analysis of the VNTR locus D1S80 by the PCR followed by high-resolution PAGE
29. Molecular analysis of the lissencephaly gene 1 (LIS-1) in medulloblastomas
30. A rapid and sensitive protocol for competitive reverse transcriptase (cRT) PCR analysis of cellular genes
31. Characterization of the human p57(KIP2) gene: Alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis
32. A device for processing large acrylamide gels
33. Monoallelic expression of the human H19 gene
34. Polymerase chain reaction (PCR) for detection of Apal polymorphism at the insulin like growth factor II gene (IGF2)
35. Locus unlinked to alpha-feto-protein under the control of the murine raf and Rif genes
36. Genomic imprinting: Mechanism and role in human pathology
37. Epigenetic lesions at the H19 locus in Wilms' tumour patients
38. Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms tumor
39. Reduced expression of the cyclin-dependent kinase inhibitor p57(KIP2) in Wilms' tumor
40. p57(KIP2) Is expressed in Wilms' tumors with LOH of 11p15.5
41. Expression, promoter usage and parental imprinting status of insulin-like growth factor (IGF2) in human hepatoblastoma: Uncoupling of IGF2 and H19 imprinting
42. Competitiona - A common motif for the imprinting mechanism?
43. Loss of imprinting in hepatoblastoma
44. Multipoint analysis of human chromosome 11p15/mouse distal chromosome 7: Inclusion of H19/IGF2 in the minimal WT2 region, gene specificity of H19 silencing in Wilms' tumorigenesis and methylation hyper-dependence of H19 imprinting
45. Multiple mechanisms regulate imprinting of the mouse distal chromosome 7 cluster
46. Disruption of imprinting caused by deletion of the H19 gene region in mice
47. Loss of imprinting of a paternally expressed transcript, with antisense orientation to KvLQT1, occurs frequently in Beckwith-Wiedemann syndrome and is independent of insulin-like growth factor II imprinting
48. Two novel genes in the center of the 11p15.5 imprinted domain escape genomic imprinting
49. Cyclin-dependent kinase inhibitor p57(KIP2) in soft tissue sarcomas and Wilms' tumors
50. p27(KIP1): Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors
51. Absence of WAF1 mutations in a variety of human malignancies
52. Mutational analysis of the human cyclin-dependent kinase inhibitor p27(KIP1) in primary breast carcinomas
53. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/KIP1 in human malignancies
54. Impact of the cyclin-dependent kinase inhibitor p27(KIP1) on resistance of tumor cells to anticancer therapy
55. New functional activities for the p21 family of CDK inhibitors
56. The p21CIP1 and p27 KIP1 CDK inhibitors are essential activators of cyclin D-dependent kinases in murine fibroblasts
57. Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors
58. The retinoblastoma protein and cell cycle control
59. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
60. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the b-catenin gene
61. Overexpression of cyclin D1 and cdk4 in tumorigenesis of sporadic hepatoblastoma
62. Biallelic inactivation of the APC gene in hepatoblastoma
63. Characterization of genomic alterations in hepatoblastomas: A role for gains on chromosomes 8q and 20 as predictors of poor outcome